Vallance-Owen and his colleagues described an insulin inhibitor associated with human plasma albumin fractions (1) (2) (3) . Inhibitory fractions were prepared by the Debro procedure (4) using plasma obtained from both normal and diabetic subjects. The existence of this inhibitor and its quantitative increase in diabetics have been confirmed by Lowy, Blanshard, and Phear (5) and Alp and Recant (6) . Other investigators, notably Keen, Cameron, and Menzinger (7, 8) , have failed in their efforts to demonstrate this material.
In view of the difficulties encountered by the latter group of investigators and since our laboratory previously described observations on a relatively small number of subjects, it seemed important to report on our more extensive experience with this inhibitor.
Human albumin fractions prepared by the Cohn fractionation procedure (9) as well as the Debro procedure were tested for insulin-inhibitory activity. We attempted to define more quantitatively the distribution of the inhibitor in normal subjects, in a variety of diabetics, and in a group of pregnant, nondiabetic women. Additional experiments were performed to clarify certain aspects of the mechanism of insulin inhibition produced by these albumin fractions.
Methods
Debro albumin fractions. Albumin fractions were prepared from the serum of 17 normal subjects, 21 diabetics, 15% over ideal body weight. Four of the normal subjects and two of the pregnant subjects tested had positive family histories of diabetes. Among the normal patients, D.H., M.L., G.L., and B.S., the diabetic relatives were in the immediate family (father, mother, or siblings). In the other two instances only a distant family member was diabetic. The pregnant women were in their third trimester of pregnancy. Their glucose tolerance tests were normal, and no complications of pregnancy were noted. Follow-up studies at term revealed that all babies were of normal size, and no major complications were encountered. Diabetic subjects were not homogeneous. Clinical data are provided in Table I . Those diabetics on specific therapy were studied 24 hours after the last insulin injection or Orinase tablet unless otherwise specified.
Cohn albumin fractions (normal albumin). Eight albumin fractions prepared by method 6 of Cohn1 represented pools of both fasted and nonfasted plasma prepared in large batches. In the text these fractions are referred to by their respective lot numbers. Three preparations of pure Fraction V were tested.2 Five preparations of crude or unreworked Fraction V were also tested: lot no. 327 (unreworked) ,2 18866, 457, 520, and 3505. 3 Methods. Albumin fractions were tested at concentrations varying from 1.25%o to 5.0%o. Insulin-inhibitory activity of these preparations was tested in vitro with a cut rat hemidiaphragm in a paired technique only partially detailed in a previous communication (6 The albumin preparation to be tested was weighed out carefully on an analytical balance and diluted in 1) Krebs-Henseleit buffer containing 250 mg per 100 ml of glucose and 200 mg per 100 ml of gelatin and 2) buffer containing glucose and gelatin plus 1,000 /AU per ml of crystalline insulin.4 Two-ml volumes of buffer, buffer plus insulin, albumin, and albumin plus insulin were added, respectively, to the incubation vessels, which were then stoppered and chilled until the tissues were ready to be added. Contact of albumin with insulin was present from the time of the original dilution until the end of the experiment. Preparation of the tissues required about 20 minutes.
Male Sprague-Dawley rats weighing approximately 160 g were fasted overnight. The animals were guillotined without anesthesia and the hemidiaphragms removed and placed immediately in chilled buffer without glucose.
Six rats were used in one experiment, and the procedure was divided into two parts so that tissues could be handled rapidly, i.e., three rats were sacrificed, tissues dissected, weighed on a torsion balance after gentle blotting, and then placed in the respective incubation vessels. After this the second group of rats was treated similarly.
The tissues were gassed gently in the closed vessels with 95% Ob-5% CO for Mean values were calculated for the glucose disappearance (milligrams glucose uptake/gram tissue/80 minutes) in the triplicate samples of buffer, albumin, buffer + insulin, and albumin + insulin. The insulin effect was described as the mean increment in glucose uptake over the mean of the respective base-line values. Inhibition of this insulin-induced increment was produced by certain albumin fractions and expressed as percentage of inhibition, considering the insulin effect in the buffer system without albumin to be 100%o. The use of "per cent inhibition" as a quantitative expression of the inhibitory activity of albumin was adopted to permit gross comparisons between individuals, since absolute insulin effects varied from experiment to experiment. Confidence limits of the assay procedure were determined on the basis of five consecutive assays in which triplicate buffer pairs and triplicate buffer pairs + 1,000 /AU per ml of insulin were compared. The mean difference between the insulin-treated pairs was 0.238 mg per g tissue with a standard error of 0.203 showing no significant difference betwen pairs. The 95%o confidence limits for the difference are -0.326 to + 0.802. No significant differences were found in any of the series of pairs of buffer alone. A highly significant insulin effect was observed in all assays (p < 0.01 to p < 0.001).
To indicate the type of variation encountered in the assay for inhibitory activity of various albumin preparations, Table II shows the raw data in an experiment with a highly inhibitory albumin preparation. The standard error of the mean (S;) is 0.372 mg per g tissue, calculated from the residual mean square in the analysis of variance. The determination of significance of the differences in insulin response was carried out by Duncan's multiple range test. In this experiment, a highly significant difference in response to insulin in the albumin sample vs. buffer is noted (p < 0.01). Table III shows similar statistical data obtained in a series of individual assays and shows the rough correlation of the per cent inhibition with the individually determined p value for the glucose uptake in the insulin pairs (buffer + insulin vs. albumin + insulin). As a result of these observations, it would seem reasonable to consider a > 40%, inhibition significant.
Results

I. Insulin-inhibitory activity of Debro fractions
Normal subjects. Table IV records data obtained with preparations of albumin from normal subjects. Section A of Table IV shows that with albumin concentrations of 3 to 3.5%, a significant inhibition of insulin action was observed in the over-all group (p = 0.05). Lower concentrations of albumin (section B of Table IV), 2.5% or less, produced, on the average, no significant inhibition of 1,000 p&U of insulin (p = NS).
Individual subjects, however, showed considerable variation in inhibitory activity. At 2.5% albumin, two normal subjects (one with a nega- tive family history of diabetes) showed 48 and 40% inhibition, whereas another normal albumin obtained from nephrotic urine showed only 29% inhibition at 3.5%o concentration of albumin. No significant degree of insulin inhibition was observed with albumin concentrations of 2%o or less in the seven normal subjects tested at this concentration. Testing of 2%o albumin obtained from four subjects with bilateral positive family histories of diabetes revealed significant inhibition in two (Table III) . Analysis of the prediabetics as a group revealed a p < 0.01 for the difference between A + I vs. B + I.
Diabetic subjects. The activities of 22 albumin preparations obtained from diabetic subjects are shown in Table V . The concentrations of albumin tested ranged from 1.25%o to 2.5%, at which level a highly significant inhibition of insulin action was found for the over-all group (p < .001). It is of interest that urine albumin obtained from two diabetic nephrotics showed insulin inhibitory action at 1.25%. Serum albumin from nephrotic patient L.H. showed 56%o inhibition; her urine albumin showed a 45% inhibition when tested at the same concentration. Albumin fractions from diabetics showed quantitatively more inhibitory activity than normal albumin, activity being demonstrable at less than 2.5% concentrations. However, 6 diabetic samples of the 22 tested showed less than 36% inhibition. In addition a wide range of inhibitory activity was observed in all samples. In an effort to understand the failure of certain diabetic subjects to show more inhibitory activity at low concentrations of albumin, new albumin preparations were made from two of these patients (H.F. and A.S.). In both cases, less than 25%o inhibition of 1,000 ,uU per ml of insulin was observed with repeat preparations. Other possible factors were examined. In the case of J. R., elevation of the base-line glucose uptake in buffer may have represented a technical error. In the cases of H.F., A.S., M.K., and the pooled samples, the experiments were technically satisfactory. It seemed possible that the severity of the diabetic state might correlate to some degree with the inhibitory activity. For this reason, inhibitory activity of albumin preparations from patients who did not require insulin was compared with inhibitory activity of those requiring treatment.
The mean inhibitory activity observed was 35%o in the noninsulin group vs. 66%o in the insulin group. The difference between these means is statistically significant at the 0.01 probability level.
That insulin treatment per se was not necessarily the factor involved in intensifying the in-hibitory activity may be seen in that patient T.L., who was not receiving insulin at the time of the test, as well as certain individuals in the group not requiring insulin, showed highly significant inhibitory activity.
Of special interest is the fact that H.F., who failed to show inhibition, is the identical twin of J.F., who showed significant inhibitory activity.
Pregnant women. Nondiabetic women in the third trimester of normal pregnancy were studied. When the over-all means of the normal, diabetic, and pregnant groups tested at albumin concentrations of 2.5% or less were compared by the analysis of variance and the method of least significant difference, it was found that the normals and diabetics differed with a p < 0.01, and the (Figure 1 ). All albumin fractions tested including the Red Cross preparations showed two to three bands but only one ultracentrifugal peak. Immunoelectrophoresis of these fractions revealed no f3-or y-globulins.
III. Mechanism of action of insulin-inhibitory albumin preparations
Effect on glycogen synthesis. Comparisons of the effects of the inhibitor on insulin stimulation of glucose uptake and glycogen synthesis in muscle were made. Table VIII shows eight albumin preparations (Debro and Cohn), with varying degrees of inhibitory activity on glucose uptake, which were examined with regard to these two parameters. A high degree of statistical correlation between inhibition of insulin effects on glucose uptake and glycogen was found. The r was 0.970 with p < 0.001. The fact that inhibition of glycogen synthesis was not greater than inhibition of glucose uptake suggests that there was no obvious impairment of phosphorylation of the glucose that was taken up by the tissue.
Free fatty acid content of albumin. One major question that has been repeatedly raised with regard to insulin inhibition by albumin preparations relation between FFA content and inhibition. One would further expect that if FFA were involved in the inhibition of insulin action, they might also inhibit the base-line uptake of glucose (14) . This certainly did not appear to be the case in that Red Cross albumin and Fraction 457, which had very high FFA contents, did not impair glucose uptake (Table VII) . Relationship of inhibitory activity to concentration of albumin. Five albumin preparations were tested at more than one concentration.
In Table VII the inhibitory activity of preparation 145 at 4%o and 5%o is shown. Four per cent concentration of 145 showed 26%o inhibition, whereas 5%go showed 36%o inhibition. Fraction 457 was tested at 1.25%, 3%, and 5%. Duplicate assays performed at 3%o and 5% are also shown in Table VII ; inhibitory activity was greater at 5%7o. At 1.25%o concentration no significant inhibition was found: the insulin effect was + 2.77 in albumin, whereas it was + 2.98 mg glucose per g tissue in buffer. Debro albumin prepared from patient H.M. (Table IV) was tested at 2.5 and 3.0% concentrations with 85%o inhibition in the latter and only 19%o in the former. C.M., also shown in Table IV, showed 13% inhibition at 1.257o% and 35%7o at 3.0%o. These observations suggest that with any one albumin preparation, there is a relationship between increasing albumin concentration and increased inhibitory activity. The data are too few to permit mathematical description of this relationship. Effect of inhibitory albumin at different concentrations of insulin. Figure 2 shows the results of studies of various concentrations of an inhibitory albumin fraction tested in the presence of 500, 1,000, and 10,000 ,uU of insulin per ml. V is the maximal increment in glucose uptake stimulated by insulin in buffer, and V1 is the increment in glucose uptake stimulated by insulin in albumin. If no inhibition is obtained, the ratio is V/Vi = 1.0. If inhibition occurs, the ratio is greater than 1.0. At higher concentrations of insulin, the inhibitory effect of the same concentration of albumin is decreased. There are too few points to provide a significant kinetic analysis of what appears to be some type of competitive inhibition. Schwert (15) is a highly satisfactory method for preparation of ultracentrifugally pure albumin utilizing an acid alcohol extraction at room temperature. The sedimentation constant, electrophoretic mobility, and patterns suggest considerable purity. Cohn's method 6 differs in that lower temperatures, varying alcohol concentrations, and an increasingly acid pH are combined in preparation of Fraction V. Clearly, both procedures yield albumin that has insulin-inhibitory properties. From the data presented here it is not possible to say whether albumin itself or a molecule associated with albumin is the inhibitor. Vallance-Owen and associates have found that the inhibitor can be separated from albumin and is a dialyzable substance (1). However, there are no data to directly support their suggestion that the inhibitory material is the B chain of insulin, since this substance has not yet been isolated from inhibitory albumin preparations (16) .
Whatever the nature of the inhibitory activity, comparisons of albumin from groups of normal individuals with groups of diabetic subjects reveal a significantly greater degree of inhibitory activity in the diabetics. Since the biological assay for the demonstration of the insulin inhibitor is subject to the statistical variations noted in this report, it seems wise at this time to consider the data as semiquantitative. There appears to be a considerable spread of activity through the normal and the diabetic groups, although a separation can thus far be made between the two, in that albumin from normal subjects has not, in our (Table  V) , serum and urine albumin preparations showed similar inhibitory activity. Certainly the loss of a potent insulin inhibitor in the urine of diabetic nephrotics might well play a role in the decreased insulin requirements of these patients. Other possible explanations for improved carbohydrate tolerance in diabetics with nephrosis have been reported (20, 21) .
With regard to the mechanism of action of this inhibitor, certain points can be made. Although insulin-inhibitory activity is demonstrable in vitro with separated albumin fractions from normal subjects, whole normal serum containing equivalent amounts of albumin does not show in vitro insulin-inhibitory activity (3). Since some normal albumin preparations at in vitro concentrations of 5% can totally impair the activity of 1,000 ,uU per ml insulin (a concentration of insulin at least 10-to 100-fold that found in normal plasma by immunoassay), it is difficult to understand how insulin can act in vivo in the normal individual if this inhibitor indeed has a physiologic action. It may well be that this insulin inhibitor is specifically concentrated by the fractionation procedures used in preparing albumin, that it may be coprecipitated, and that we are in no position to quantify the actual concentration of insulin inhibitor in the circulation or available to the tissues.
In an earlier paper Alp and Recant (6) demonstrated that these albumin preparations had no insulin-inhibitory effects upon adipose tissue. In fact these preparations contained measurable amounts of endogenous insulin plus the capacity to enhance the action of added insulin on the glucose metabolism of fat. Keen and associates also stated that Debro preparations of albumin contained insulin (7, 8) . Despite the presence of insulin, these preparations in our hands may still be actively inhibitory of insulin action on muscle. In fact preparations of diabetic albumin contained as much or more insulin than normal preparations (6) . However, the insulin content of these preparations tested at 2% concentrations is insignificant (0 to 30 1AU per ml by immunoassay) relative to the 1,000 1AU per ml of insulin that is added. It would seem likely that the inhibitor competes with insulin. This competition does not appear to be for gross binding of insulin to the tissue. Why adipose tissue and muscle behave so differently with regard to this inhibitor cannot be definitely answered. In view of the observations of Froesch and Ginsburg (22) and Frerichs and Ball (23) with regard to effects of insulin on the metabolism of fructose and glucose by adipose tissue and the inhibitory effects of phlorizin on insulin action, it is difficult to accept a basic difference in membrane response to insulin in muscle and fat cells. On the other hand, totally different responses of adipose tissue to substances known to inhibit insulin action in muscle have been observed. FFA clearly inhibit muscle glucose metabolism, and they may stimulate glucose responses to insulin in adipose tissue (24, 25) . It may be that adipose tissue possesses enzymes capable of altering inhibitors. There is precedence in the reports of Antoniades and Gundersen (26) and Shaw and Shuey (27) for such a hypothesis. These investigators have shown that adipose tissue and adipose tissue extracts release insulin from a complexed form to a free form, but no such activity can be attributed to muscle. It might be postulated that some destruction of the albumin inhibitor is produced by adipose tissue. In fact, Ensinck and VallanceOwen reported findings suggestive of this (28) . In our preliminary experiments, partial loss of inhibitory activity occurs after incubation of albumin preparations with adipose tissue. However, a similar loss of activity occurs after incubation with muscle.
Although there are a multitude of unanswered questions concerning this inhibitor associated with plasma albumin, it is likely that further studies, particularly in the direction of separation and identification of the active substance, may provide more precise knowledge of the origin and role of this material in the diabetic state.
Summary
Human plasma albumin fractions prepared either by the Debro procedure or Cohn method 6 were associated with significant insulin-inhibitory activity when tested in vitro with rat diaphragm muscle. Diabetic subjects showed quantitatively more inhibitory activity than normals. Pregnant women in the third trimester appeared to have more inhibitory activity than normal but probably less than diabetic. The mechanism of insulin inhibition appears to be competitive and is not quantitatively related to the free fatty acid content of albumin preparations.
